203 related articles for article (PubMed ID: 28834238)
1. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
[TBL] [Abstract][Full Text] [Related]
2. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
[TBL] [Abstract][Full Text] [Related]
3. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
4. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
[TBL] [Abstract][Full Text] [Related]
6. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
8. The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
Nowak-Göttl U; Dietrich K; Kruempel A; Geisen C; Mitchell LG
Blood Cells Mol Dis; 2017 Sep; 67():54-58. PubMed ID: 28284562
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
Misasi S; Martini G; Paoletti O; Calza S; Scovoli G; Marengoni A; Testa S; Caimi L; Marchina E
Medicine (Baltimore); 2016 Dec; 95(52):e5451. PubMed ID: 28033245
[TBL] [Abstract][Full Text] [Related]
12. Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices.
Brehm K; Krumnau O; Heilmann C; Beyersdorf F
Eur J Cardiothorac Surg; 2016 Aug; 50(2):275-80. PubMed ID: 26984978
[TBL] [Abstract][Full Text] [Related]
13. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
14. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.
Perreault S; Shahabi P; Côté R; Dumas S; Rouleau-Mailloux É; Feroz Zada Y; Provost S; Mongrain I; Dorais M; Huynh T; Kouz S; Diaz A; Blostein M; de Denus S; Turgeon J; Ginsberg J; Lelorier J; Lalonde L; Busque L; Kassis J; Talajic M; Tardif JC; Dubé MP
Clin Cardiol; 2018 May; 41(5):576-585. PubMed ID: 29542828
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics aspects of oral anticoagulants therapy.
Militaru FC; Vesa SC; Pop TR; Buzoianu AD
J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
[TBL] [Abstract][Full Text] [Related]
19. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
Lacut K; Ayme-Dietrich E; Gourhant L; Poulhazan E; Andro M; Becquemont L; Mottier D; Le Gal G; Verstuyft C
Br J Clin Pharmacol; 2012 Mar; 73(3):428-36. PubMed ID: 21883387
[TBL] [Abstract][Full Text] [Related]
20. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]